Key Takeaways
- Cosmos Health has filed a patent application for an AI-discovered allergic inflammation therapy.
- The company’s Cloudscreen AI platform identified a repurposed drug with a novel mechanism of action.
- The global allergy treatment market, valued at $23.5 billion, is projected to grow to $37 billion by 2033.
Cosmos Health Inc. (NASDAQ: COSM) has submitted a new patent application for an innovative allergic inflammation therapy, leveraging its AI-driven drug repurposing technology. Developed in collaboration with Cloudpharm and the National Hellenic Research Foundation, the therapy targets immune system hypersensitivityseen in conditions such as allergic rhinitis, asthma, and food allergies.
The patent is supported by predictive modeling and experimental data, demonstrating the potential of a marketed drug repurposed to regulate key inflammatory pathways. With allergic conditions affecting up to 30% of the global population, Cosmos Health aims to introduce a novel, more effective treatment approach.
AI-Driven Innovation in a Growing Allergy Market
The global allergy treatment market, currently valued at $23.5 billion, is set to expand as allergic conditions continue to rise. With its AI-powered Cloudscreen platform, Cosmos Health is positioning itself at the forefront of allergy research, offering faster, cost-effective drug discovery solutions.
By integrating AI insights with cutting-edge experimental validation, Cosmos Health continues its mission to redefine treatment options for inflammatory diseases, ensuring better patient outcomes worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
